AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases Financing round led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital. AbolerIS is developing a first-in-class drug inducing an immune tolerance-based mechanism that acts…
Artialis appoints Benedikt Van Nieuwenhove as its new CEO August 1st, 2023 Liège, Belgium – Artialis SA, a CRDO company offering preclinical, clinical and biotesting services, is pleased to announce Benedikt Van Nieuwenhove as its new Chief Executive Officer (CEO). Prof. Yves Henrotin, founder and former CEO of the company, will…
SPUTUMAI, a new diagnostic tool for severe forms of asthma Cytomine, ZORGI, the University of Liège and the University of Brussels, working as a consortium, have just been awarded €2 million in funding from Wallonia as part of a call for projects launched by the MecaTech and BioWin competitiveness clusters….
BioWin: Renewal of the Board of Directors. Reflecting on a successful journey BioWin, the Health Cluster of Wallonia, Belgium, announces today the renewal of its Board of Directors and provides an overview of its achievements over the past years. New vision and leadership BioWin’s Board of Directors, the cluster’s key…
Mont-Saint-Guibert, Belgium, 2023/06/20: Cellaïon is a biotechnology company based in Mont-St-Guibert, active in the field of liver regenerative advanced therapy, an area of excellence in the life sciences industry in Wallonia. Its flagship product HepaStem®, in advanced clinical development, targets severe liver diseases, and in particular Acute on Chronic Liver…
Business Village Ecolys
Avenue d’Ecolys 2
5020 Namur (Belgium)
Email : contact@biowin.org
VAT BE 0882.768.591
Website by Monkeys not Donkeys
© 2023 BioWin.
